Ivermectin carries a retail price of around $40 for a standard prescription in the United States, though discount programs can bring that down to roughly $11 to $25 for a pack of eight 3mg tablets. For a drug that has been off-patent for decades and costs pennies to manufacture in countries like India, that price tag surprises many people. Several overlapping factors explain the gap between what ivermectin costs to make and what you actually pay at the pharmacy counter.
What You Actually Pay at the Pharmacy
The sticker price for ivermectin varies widely depending on where you fill your prescription and whether you have insurance. The listed retail price sits around $40 per fill, but pharmacy discount cards and coupons can cut that to somewhere between $11 and $25 for a standard eight-tablet pack. If your insurance covers the prescription, your copay could be lower still, but many plans either don’t cover ivermectin for certain uses or place it on a higher copay tier, leaving you closer to that retail number.
Your final out-of-pocket cost depends on your treatment plan, your insurance coverage, and which pharmacy you use. Prices also shift by region. A prescription filled at a chain pharmacy in one state may cost meaningfully more or less than the same fill across state lines.
A Wild Ride in Pricing History
Ivermectin’s price history over the past decade has been anything but stable. Tracking data from 2014 through 2023 shows dramatic swings in the average cost per prescription fill. In 2014, the average fill cost about $265. By 2016, that had climbed to $401. It briefly dropped to around $142 in 2018 before shooting up to $519 in 2019 and peaking at $564 in 2021. Then prices collapsed: the average fill fell to roughly $94 in 2022 and $135 in 2023.
The 2020 and 2021 spike lines up with the surge in demand during the COVID-19 pandemic, when interest in ivermectin as an off-label treatment drove prescriptions sharply upward. When demand spiked faster than supply could adjust, prices followed. The subsequent crash in 2022 reflects the cooling of that demand once public health messaging and clinical trial data reduced off-label prescribing. These kinds of demand-driven swings are unusual for a decades-old generic drug, and they illustrate how quickly prices can move when a small-market medication suddenly attracts mass attention.
The Manufacturing Cost Is Tiny
One reason the U.S. price feels so high is that the raw ingredient itself is genuinely cheap to produce. Ivermectin’s active pharmaceutical ingredient can be manufactured at very low cost, particularly at facilities in India where most of the world’s generic drug production is concentrated. A course of treatment in low-income countries costs a fraction of what Americans pay. The enormous markup between manufacturing cost and pharmacy price isn’t unique to ivermectin. It’s a feature of the U.S. drug pricing system, where regulatory fees, distribution margins, and pharmacy markups layer on top of one another.
Supply chain disruptions can also push ingredient costs higher. During the early pandemic, manufacturing and shipping bottlenecks affected many generic drugs. Some countries began exploring domestic production to reduce dependence on overseas suppliers, but that comes with higher overhead: building dedicated facilities, hiring specialized staff, and meeting local regulatory standards all add cost that gets passed along to the buyer.
Regulatory Fees Add Up
Every generic drug sold in the United States carries a layer of regulatory cost that most consumers never see. Under the Generic Drug User Fee program, the FDA charges manufacturers a series of annual fees just to stay in the market. Filing a new generic drug application costs about $358,000. Maintaining a drug master file for the active ingredient runs over $102,000 per year. On top of that, every manufacturing facility pays an annual fee: roughly $239,000 for a domestic facility that produces finished tablets, or about $254,000 if that facility is overseas (the extra $15,000 covers the cost of international FDA inspections).
Companies also pay a yearly program fee based on the size of their generic drug portfolio. A large manufacturer with 20 or more approved generics pays over $1.9 million annually. Even a small company with five or fewer approved products owes nearly $192,000 each year. These fees fund the FDA’s ability to review and inspect generic drugs, but they represent a fixed cost that manufacturers spread across their product lines. For a niche drug like ivermectin, which has a relatively small U.S. patient base outside of periodic demand spikes, each prescription absorbs a larger share of those fixed costs than a blockbuster generic like ibuprofen would.
Limited Competition in a Small Market
Ivermectin is primarily used in the U.S. to treat parasitic infections like strongyloidiasis and onchocerciasis, along with certain cases of scabies and head lice. That’s a relatively small patient population compared to drugs for blood pressure or cholesterol. When the market for a generic is small, fewer manufacturers bother entering it. The regulatory fees alone can make it unprofitable unless a company can charge enough per prescription to recoup those costs.
With fewer competitors, there’s less downward pressure on price. This is a pattern seen across many older generic drugs in the U.S.: medications that serve small populations sometimes cost far more than their manufacturing expense would suggest, simply because only one or two companies produce them and there’s no competitive reason to lower the price. When demand surged during the pandemic, the small number of suppliers couldn’t scale quickly, which amplified the price spike.
Insurance Gaps and Pharmacy Markups
Insurance coverage for ivermectin is inconsistent. Some plans cover it readily for FDA-approved parasitic infections but exclude it for off-label uses. Others place it on higher formulary tiers with larger copays. If your plan doesn’t cover ivermectin at all, you’re paying the full retail price, which reflects the pharmacy’s own markup on top of the wholesale cost.
Pharmacy benefit managers, the companies that negotiate drug prices between insurers and pharmacies, also play a role. In some cases, PBMs have historically prevented pharmacists from telling you when paying out of pocket with a discount card would be cheaper than using your insurance. Several states have passed laws banning these “gag clauses,” so your pharmacist should now be able to flag a cheaper option if one exists. It’s worth asking directly whether a discount program or different pharmacy would lower your cost, because the price difference can be substantial.
Why It Costs So Little Elsewhere
The price gap between the U.S. and the rest of the world comes down to system-level differences. Countries with centralized drug purchasing, like India and many nations in Africa and Southeast Asia, negotiate directly with manufacturers and accept products from local generic producers who face far lower regulatory barriers than the U.S. system imposes. Production costs at Indian generic facilities are low, capital investment in new facilities is minimal, and government price controls keep markups tight.
In the U.S., every step of the chain adds cost: FDA user fees, facility inspections, wholesale distribution, pharmacy dispensing fees, and the absence of government price negotiation for most drugs. None of these costs reflect the complexity of making the drug itself. Ivermectin is straightforward to synthesize and has been produced at scale for decades. The price you pay is almost entirely a product of the system that delivers it to you, not the molecule inside the tablet.